Rossa Brugha
Great Ormond Street Hospital, London, United Kingdom
Significant advances have been made over the past two decades with respect to our understanding and management of children with diseases that in the past would be expected to lead to lung failure. In this talk we will consider the pathway that has resulted in widespread use of cystic fibrosis modulator therapy, and how this approach might be adapted for other rare disorders including interstitial lung diseases; we will also cover some of the newer agents available in pulmonary vascular disease. Finally we will look at indications and strategies to support technology-dependent children at home.